BY D E C L A N B U T L E R
T he Ebola crisis in West Africa is approaching the one-year mark, with no clear end in sight. At present, fewer than one in five people with Ebola is diagnosed within two days of becoming infectious, according to the World Health Organization (WHO). Yet in the absence of a safe and effective vaccine, the only way to end the epidemic is to quickly identify and quarantine people who have been infected.
A major problem is that relatively few laboratories in West Africa have the necessary equipment and personnel to test blood samples from people thought to have Ebola (see 'Delayed diagnoses'). But that could soon change. Experts are gathering in Geneva, Switzerland, on 12 December to work out which diagnostic tools could be used wherever Ebola strikes.
The meeting, convened by the WHO and the non-profit Foundation for Innovative New Diagnostics (FIND), also in Geneva, seeks to identify tests that can be used by untrained staff, do not require electricity or can run on batteries or solar power and use reagents that can withstand temperatures of 40 °C. Experts will also discuss how such diagnostics could be rolled out widely in Ebola-stricken areas, and will develop a six-month plan to improve access to testing. If the push succeeds, it would mark an important strategic shift in efforts to end the epidemic.
In addition to reducing Ebola's spread, localized testing of cases would minimize care delays, says Daniel Kelly, an infectious-disease researcher at the University of California, San
Francisco, who has been working in Sierra Leone (see Nature 513, 145; 2014). People die from Ebola when the rapid fluid loss from bleeding, vomiting and diarrhoea causes the heart to stop pumping blood and other organs to fail. "Every second counts, " Kelly says. "A faster time to an Ebola diagnosis will save lives. "
Most available tests for the virus rely on a technology called reverse-transcriptase polymerase chain reaction (RT-PCR), which detects genetic sequences specific to Ebola in blood, serum and other bodily fluids. These methods are highly sensitive, but require skilled scientists working in sophisticated labs that have high-level biocontainment measures. Access to consistent power supplies and refrigeration is essential, and the tests are expensive, at roughly US$100 apiece.
These requirements put such diagnostic tools out of reach of many hard-hit parts of West Africa, prompting the WHO to establish on 18 September an emergency mechanism for reviewing other, experimental tests. Those that seem promising will be sent to independent laboratories to assess whether they live up to their manufacturers' claims; tests that succeed will be cleared for purchase by the WHO and other United Nations agencies, under a oneyear emergency authorization.
PROMISING START
So far, the WHO has received 17 applications from diagnostic companies. Although it has not released the list of candidates, many of the likely contenders and competing technologies are known.
They include 13 RT-PCR tests, many of which have been modified to make them easier to use. Several are at least partially automated: the ones that are easiest to use involve loading a blood sample into the machine, pushing a button and waiting for results that can arrive in as little as an hour. Some of the systems have also been adapted for use in harsh field environments. Mark Perkins, FIND's chief scientific officer, expects that the WHO will approve some of these tests early next year.
The other four candidates are tests that detect antigens to Ebola in blood and other fluids -in many cases, using the same strip format and analytical technique, called enzyme-linked immunosorbent assay (ELISA), as over-the-counter pregnancy-test kits. Such tests are cheap to mass produce, do not require electricity or refrigeration and use just a drop of blood.
There are some potential drawbacks, however. The strip-format ELISA used in pregnancy-test-like diagnostics tend to be several orders of magnitude less sensitive than RT-PCR, so may not be able to detect Ebola just after symptoms appear, 
DECEMBER: MIXED SIGNALS
Arriving at an Ebola treatment centre outside Sierra Leone's capital, Freetown, I heard celebratory singing and clapping: three survivors of the disease were preparing to leave. Staff at the centre in Kerry Town, which is run by the non-profit organization Save the Children, presented the survivors with laminated certificates documenting their Ebola-free status.
Almost a year after the first Ebola cases were reported, there are signs of hopesuch as these survivors. But the number of cases is still rising in some areas in Sierra Leone, including Freetown, and there are still not enough treatment beds for everyone. There is no single reason why the epidemic is still growing in parts of Sierra Leone, but a contributing factor is the difficulty of convincing people who have never previously experienced the disease to change the way that they live, care for the sick and bury the dead.
DECEMBER: CLOSE TO HOME
"From the back, from the back!" shouts Halima Shyllon, the nurse matron of a newly opened Ebola treatment centre in Makeni.
She and two workers are supervising doctor Moges Tadesse as he removes the hooded Tyvek suit that he has been wearing to treat patients for the past hour.
Before this treatment centre opened on 24 November, people with Ebola were sent elsewhere in the country, to wherever there was a bed available. Their families often never saw or heard from them again, because many died in remote care facilities.
The Makeni centre, the district's first, is run by the African Union and is largely staffed by Africans: Shyllon works for Sierra Leone's health ministry, and Tadesse is Ethiopian. There are Ugandan doctors on site and Nigerian workers will arrive soon.
One patient, Usman Fofanah, was so sick when he arrived in Makeni a few days ago that he does not remember the journey from Port Loko, about 80 kilometres away. Fofanah has lost his grandmother, an aunt and two sisters to Ebola. Still, he is smiling: he feels much better and yesterday he was able to speak by phone to his mother, who had feared him dead.
DECEMBER: IN QUARANTINE
When we arrive at the school in Tambiama, in the Bombali district of northern Sierra Leone, a few people stand in a dirt yard behind a strip of red and white quarantine tape. As a policeman and a soldier call to the rest, the men, women and children slowly file out -the friends and neighbours of a woman who died from Ebola on 14 November.
When a local priest asks how they feel, the 40 or so villagers all say that they are fine; a few even break into a spontaneous dance to prove it. If all goes well, they will be free in a matter of days. But they are restless. "They are not feeling good at all -there [is] no free movement, " says Shekub Mansary, a health worker who is translating for James Koroma, a former teacher at the primary school.
Quarantines have been widely deployed in this outbreak, but they are a crude tool. Bombali district has been under quarantine since September; only vehicles with special permissions can enter or leave. But on a recent day (6 December), there were 11 new Ebola cases. And although 1 million Sierra Leoneans now live in quarantined districts, Ebola is still infecting new areas.
People resent, and sometimes resist, the restrictions. A few weeks ago, villagers near Tambiama fought off quarantine officers with machetes.
Early on, there were problems guaranteeing that quarantined families in many areas had enough to eat. Such conditions make opposition to quarantine understandable, says Catherine Bolten, an anthropologist at the University of Notre Dame in Indiana. "You might or might not get Ebola, but you'd definitely know if you're starving to death." ■
EYEWITNESS ACCOUNT
A report from the front line tests use different technologies that are likely to detect Ebola early in its course.
The accuracy of antigen-based Ebola tests is of particular concern in Africa, because individuals there often carry antigens to several viruses and parasites, such as those that cause malaria, tuberculosis and hepatitis, which might muddy the results for Ebola. Tests that work well in the lab against blood and serum that have been artificially spiked with Ebola may not cope as well with clinical samples gathered in the field.
But Robert Garry, a virologist at Tulane University in New Orleans, Louisiana, who is developing an antigen-based Ebola strip test, is nonetheless confident about that approach after successfully developing a similar diagnostic for Lassa fever. Garry, who is working with diagnostics firm Corgenix of Bloomfield, Colorado, has just completed initial field trials of his Ebola test in Sierra Leone. "It's looking very good, " he says.
Perkins is cautious. Until all the new Ebola tests are tried in the field, and independently evaluated by the WHO, "the jury is still out", he says. ■
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DELAYED DIAGNOSES
Laboratories (L) that can diagnose Ebola are in short supply in West Africa, and are often far from areas where the epidemic is most severe. 
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